82 results about "Programmed death" patented technology

This disclosure provides a method for treating a subject afflicted with a lung cancer, which method comprises administering to the subject therapeutically effective amounts of: (a) an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity; and (b) an antibody or an antigen-binding portion thereof that specifically binds to a Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) and inhibits CTLA-4 activity.

The present application provides antibodies including antigen binding fragment thereof that specifically recognizing programmed cell death 1 ligand 1 (PD-L1). Also provided are methods of making and using these antibodies.

Described herein are gene features that provide prognosis, diagnosis, treatment and molecular subtype classification of cancer by genomic and epigenomic profiling, including immune checkpoint regulators such as Programmed Death Ligand 1 (PDL-1). Using the methods and compositions described herein, specific and sensitive detection of biomarkers of interest is provided. Such biomarkers indicate disease pathogenesis, which provides opportunities for selection of treatments, including treatment regimens intended to overcome tolerance mechanisms.

The present application relates to the technical field of biotechnology, in particular to a programmed death receptor ligand 2 monoclonal antibody and application thereof. The present application provides a PD-L2 monoclonal antibody, amino acid sequences of three CDR regions of a heavy chain thereof; amino acid sequences of three CDR regions of a light chain thereof; or amino acid sequences obtained by substitution, deletion or addition of one or more amino acids of the amino acid sequences, or amino acid sequences functionally identical or similar to the amino acid sequences; or amino acid sequences having at least 80% homology with the sequences. The present application widens the possibility of antibody therapy for blocking PD1 / PD1 ligand, and compared with existing PD-L2 monoclonal antibodies, the 8E3 antibody has unique amino acid sequences and CDR region sequences, high affinity and high specificity. The 8E3 antibody can be used in ELISA, Western blot and flow cytometry detection, and has wide application.

Provided herein are binding molecules that bind to programmed cell death protein 1 (PD-1). Such binding molecules block the interaction between PD-1 and programmed death-ligand 1 and 2 (PD-L1 and PD-L2). Also provided herein are methods of using such binding molecules for preventing and treating cancer.

The invention relates to the technical field of biological medicines, in particular to a polypeptide targeting B cell lymphoma cells, a targeting effect conjugate and application of the polypeptide and the targeting effect conjugate. Wherein the peptide chain length of the polypeptide targeting the B-cell lymphoma cells is 12 amino acids, and the polypeptide is selectively and specifically combined with the B-cell lymphoma cells. The targeting effect conjugate is formed by connecting polypeptide and pro-apoptotic peptide through a connecting peptide. The pro-apoptotic peptide can induce programmed death of target cells by destroying a mitochondrial membrane structure. The molecular weight of the polypeptide is small, the chemical synthesis process is simple, convenient and efficient, high consistency between different batches of products can be ensured in the synthesis process, and a guarantee is provided for subsequent quality control. The small molecular structure is also convenient for sequence optimization and terminal modification, can create extremely favorable conditions for subsequent structure-function relationship research and pharmaceutical development work, and is helpful for accelerating the research and development process of novel therapeutic drugs.

The invention provides pharmaceutical compositions of anti-PD-1 antibodies or antigen-binding fragments thereof with less than or equal to about 3.0% oxidation of Met105 in the CDRH3 heavy chain region, and PH20 variants or fragments thereof. The invention also provides pharmaceutical compositions comprising anti-PD-1 antibody main species and acidic species thereof, wherein the amount of acidic species is about 1.0-12.0%, and PH20 variants or fragments thereof.

The disclosure provides a method of treating a human subject afflicted with lung cancer with a lymphocyte activation gene-3 (LAG-3) antagonist. In some aspects, the method comprises combination of the LAG-3 antagonist with an additional therapeutic agent (e.g., a programmed death-1 pathway inhibitor) and / or anti-cancer therapy (e.g., chemotherapy such as a platinum doublet chemotherapy).

This disclosure provides methods for treating tumors, reducing tumor severity, inhibiting tumor growth, or inducing tumor necrosis, wherein the methods include: selecting a patient with cancer (e.g., liver cancer, lung cancer, or head and neck cancer) in need of treatment and administering neoadjuvant therapy to the patient in a combination of a therapeutically effective amount of a programmed death 1 (PD-1) inhibitor (e.g., cimiprimab or its bioequivalent) and radiation therapy (e.g., SBRT) or an anti-LAG-3 antibody (e.g., fenpromab), followed by surgical resection and optionally administration of a programmed death 1 (PD-1) inhibitor (e.g., cimiprimab or its bioequivalent) as postoperative adjuvant therapy. In some embodiments, the cancer is liver cancer, such as hepatocellular carcinoma (HCC).

The invention belongs to the technical field of cell cryopreservation, and particularly relates to a cell cryopreservation solution, application thereof and a cell cryopreservation method. A death inhibitor and a solvent are selected for specific cells, and the cell death process related to cytolytic organelle membrane damage is intervened from the molecular level, specifically, the solvent is used for reducing ice crystal formation inside and outside the cells, the membrane protection effect is exerted to achieve the high resuscitation motility rate, a programmed death pathway is further blocked in a targeted mode through the death inhibitor, and the cell death effect is improved. The programmed death after cell resuscitation is relieved, the delayed death rate of the resuscitated cells is reduced, the long-term cell fusion degree of the resuscitated cells is improved, and the long-term survival rate of the resuscitated cells is improved.

A programmed cell death ligand 1 (PD-L1) targeting polypeptide, a molecular imaging probe, and a use thereof are provided. The PD-L1 targeting polypeptide includes any one of the following polypeptides: (1) a polypeptide shown in at least one of SEQ ID NO: 1 to SEQ ID NO: 9; and (2) a polypeptide that is derived from an amino acid sequence of (1) through a substitution and / or a deletion and / or an addition of one or more amino acid residues and has the same function as the amino acid sequence. The magnetic resonance molecular imaging probe based on the PD-L1 targeting polypeptide enables the early diagnosis and evaluation of a tumor and an immune-mediated myocardial injury.

Provided are methods for determining if an individual is likely to experience immune-related adverse events (irAEs) if treated for melanoma with a combination of immune checkpoint inhibitors that are an anti-Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) antibody and an anti-programmed death-ligand 1 (PD-1) antibody. The methods include determining differential gene signatures as between individuals who had melanoma and were treated with a combination of a CTLA-4 antibody and an PD-1 antibody but did not experience severe irAEs after the treatment, with the gene signature for an individual who has melanoma but was not treated with an immune checkpoint inhibitor.

This disclosure provides methods for treating endometrial cancer, reducing its severity, or inhibiting its growth. The methods of this disclosure comprise administering to a subject in need a single therapeutically effective amount of a bispecific antibody that specifically binds to mucin 16 (MUC16) and CD3, or administering said bispecific antibody in combination with a therapeutically effective amount of an antibody specifically binding to the programmed death 1 (PD-1) receptor or an antigen-binding fragment thereof.

An immune related adverse event marker and a kit. The immune related adverse event marker comprises CD183. The immune related adverse event marker can effectively predict immune related adverse events caused by programmed death receptor 1 antibody / programmed death-ligand antibody therapy, thereby facilitating intervention and treatment of immune related adverse events.

The invention belongs to the technical field of biological medicines, and particularly relates to application of gamma-mangosteen in preparation of a medicine for treating cold tumors. The invention also relates to application of gamma-mangosteen or pharmaceutically acceptable salts, solvates or prodrugs thereof in preparation of drugs for treating cold tumors. The invention discloses an application of gamma-mangostein in preparation of a medicine for treating cold tumors, and aims to solve the technical problems of drug resistance and low response of a programmed death receptor-1 (PD-1) inhibitor in treatment of cold tumors by targeted degradation of HSF1 protein and remodeling of a tumor immune microenvironment.

A population of universal natural killer (NK) cells derived from human pluripotent stem cells (hPSCs) and engineered to overexpress the transcription factor ID2, NFIL3, and / or SPI1 and, optionally, an anti-programmed death ligand 1 (PD-L1) chimeric antigen receptor (CAR) and an anti-fluorescein isothiocyanate CAR are provided. Methods of treating cancer in a subject using the population of universal NK cells are also provided.

The present disclosure relates generally to antibodies and functional binding fragments thereof that bind to programmed death-ligand 1 (PD-L1). In particular, the disclosed antibodies and fragments bind to human PD-L1 and comprise novel complementary determining regions (CDRs) also disclosed herein. Finally, the present disclosure relates to administering the disclosed antibodies and fragments to subjects with cancer, thereby treating or slowing the progression or proliferation of the cancer.

The present invention provides anti-PD-L1 antigen binding molecules, including antibodies and the antigen binding fragment thereof, and methods for using the same for treating a variety of diseases, including cancers.

The invention belongs to the technical field of radiopharmaceutical chemistry, and particularly relates to a programmed death ligand-1 (PD-L1) targeted radioactive polypeptide probe as well as a preparation method and application thereof. The PD-L1 targeted radioactive polypeptide probe structurally comprises a PD-L1 targeted polypeptide ligand, a targeted / metabolic functional regulating group, a radionuclide chelating group and a radionuclide (such as 68Ga). According to the radioactive polypeptide probe provided by the invention, on the basis of a PD-L1 targeted polypeptide motif, a chelating group is introduced to label radionuclide, and the radioactive polypeptide probe is mainly used for diagnostic imaging. And a functional regulating group, namely a 5-(trifluoromethyl) pyridine-3-carboxylic acid group, is inserted for improving targeting and in vivo metabolism. The radioactive polypeptide probe has excellent tumor targeting property and remarkable tumor retention capacity, shows good in-vivo stability and pharmacokinetic characteristics, and is easy to synthesize. The method can help to screen potential benefited patients of the PD-1 / PD-L1 immunotherapy, and can quickly and accurately monitor real-time and dynamic changes of PD-L1 in the tumor immunotherapy process so as to predict and evaluate the effect of the PD-1 / PD-L1 immunotherapy.

Provided are methods and compositions for treating cancer, such as non-small cell lung cancer, head and neck cancer, esophageal cancer, ovarian cancer, melanoma, breast cancer, and gastric cancer, in a subject, such as by the administration of antibodies and antibody-drug conjugates that bind to Programmed Death-Ligand 1 (PD-L1).

Provided herein are binding molecules that bind to programmed cell death protein 1 (PD-1). Such binding molecules block the interaction between PD-1 and programmed death-ligand 1 and 2 (PD-L1 and PD-L2). Also provided herein are methods of using such binding molecules for preventing and treating cancer.

This disclosure relates to a class of engineered peptides with binding affinity for programmed death-ligand 1 (PD-L1), and provides a sequence comprising ERNX4AAX7EIL X 11 LPNLX 16 X 17 X 18 QX 20 WAFIWX 26 LX 28 PD-L1-binding peptides of type D. This disclosure also relates to the use of such PD-L1-binding peptides as therapeutic agents, prognostic agents, and / or diagnostic agents.

The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof. In some embodiments the formulations of the invention comprise between 5-200 mg / mL anti-PD-1 antibody, or antigen binding fragment thereof. The invention further provides methods for treating various cancers with stable formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by intravenous or subcutaneous administration.

The invention discloses application of 19-hydroxybufalin in preparation of a medicine for treating prostatic cancer, and belongs to the technical field of pharmaceutical preparations. The 19-hydroxybufalin is found to be targeted in vivo and in vitro for the first time, and the growth of prostate tumors is remarkably inhibited, so that the survival basis of tumor cells is fundamentally weakened, programmed death of the tumor cells is triggered, and tumor regression is effectively induced; a brand-new treatment approach is provided, namely, a non-classical drug target, namely HELLS, is degraded in a targeted manner, so that a new treatment choice is expected to be provided for a patient lacking existing target mutation; the provided 19-hydroxybufalin can be used for treating advanced prostate cancer, especially castration-resistant prostate cancer, and a new candidate treatment drug with great potential and a brand new treatment strategy are provided for effectively solving the problem that chemotherapy drug resistance and targeted therapy selection are limited in the castration-resistant prostate cancer at present.

The invention belongs to the field of biotechnology and medicine, provides application of thioredoxin TXN1 and TRP14 as a bidirectional switch for regulating and controlling a cell death mode and application of an anti-cancer drug, and particularly relates to new application of TXN1 and TRP14. The invention reveals that TXN1 and TRP14 play a role of a bidirectional regulation switch in regulating the sensitivity of non-small cell lung cancer cells to different programmed death modes (including apoptosis, ferroptosis and disulfide death) for the first time. By reducing the activity or expression of TXN1 or TRP14, the sensitivity of cancer cells to apoptosis inducers and ferroptosis inducers can be enhanced, but the resistance of the cancer cells to glucose deprivation-induced disulfide death is remarkably enhanced. The discovery shows that inhibition of TXN1 / TRP14 can be combined with an apoptosis / ferroptosis inducer to treat cancers; meanwhile, an inhibitor aiming at TXN1 / TRP14 can be used for preventing or treating diseases related to disulfide death. The invention provides a cancer treatment composition based on the discovery, a drug screening method and biomarker application.

The present disclosure provides methods for treating a subject having lung cancer, the methods comprising administering to the subject a therapeutically effective amount of: (a) an antibody or antigen-binding portion thereof that specifically binds to the Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity; and (b) an antibody or antigen-binding portion thereof that specifically binds to Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) and inhibits CTLA-4 activity.

The disclosure relates to methods for treating or inhibiting the growth of a tumor, wherein the methods include selecting a subject with a skin cancer and intralesionally administering to the tumor of the subject in need thereof a therapeutically effective amount of a programmed death 1 (PD-1) inhibitor (e.g., an antibody or antigen-binding fragment thereof that specifically binds PD-1, PD-L1, and / or PD-L2). In certain embodiments, the skin cancer is cutaneous squamous cell carcinoma. In certain embodiments, the PD-1 inhibitor is administered into multiple locations of the tumor lesion.

Described herein are gene signatures providing prognostic, diagnostic, treatment and molecular subtype classifications of cancers through genomic and epigenomic profiling, including immune checkpoint regulators such as programmed death ligand 1 (PDL-1). Using methods and compositions described herein, specific and sensitive detection of biomarkers of interest is provided. Such biomarkers are indicative of disease pathogenesis, which provides opportunity for selection of treatment, including treatment regimes directed at overcoming resistance mechanisms.

The presently disclosed subject matter provides compositions, kits, and methods that include imaging agents capable of detecting programmed cell death ligand 1 (PD-L1). The imaging agents of the present disclosure can be used to detect diseases and disorders in a subject, such as cancer, infection, and inflammation.

The invention provides pharmaceutical compositions of anti-PD-1 antibodies or antigen-binding fragments thereof with less than or equal to about 3.0 % oxidation of Met105 in the CDRH3 heavy chain region, and PH20 variants or fragments thereof. The invention also provides pharmaceutical compositions comprising anti-PD-1 antibody main species and acidic species thereof, wherein the amount of acidic species is about 1.0-12.0%, and PH20 variants or fragments thereof.